BiotechTube
Home/Nanomerics/Dr. Alan Bye
DA

Dr. Alan Bye

Non-Executive Director

Nanomerics

Therapeutic Areas

OphthalmologyCentral Nervous System (CNS)

Nanomerics Pipeline

DrugIndicationPhase
OC134Ophthalmology (unspecified)Phase 1
Envelta™ (NB127)Non-addictive analgesic (CNS)Partnered (Virpax)
METfect PlatformGenetic CNS disordersPre-clinical

Leadership Team at Nanomerics

DA
Dr. Andreas G. Schätzlein
CEO & Co-founder
DI
Dame Ijeoma Uchegbu
CSO & Co-founder
AM
Andrea Mica
Non-Executive Director
View full Nanomerics profile